美股A股
StockGist
Back
8-K2026-05-13· deepseek-chat

MIRA · MIRA Pharmaceuticals, Inc.

0001493152-26-022704

SEC filing

Summary

MIRA Pharmaceuticals announced positive Phase 1 results for Ketamir-2, showing favorable safety and pharmacokinetics, supporting advancement to Phase 2a in CIPN.

Key takeaways

Full analysis

MIRA Pharmaceuticals disclosed positive unblinded results from its completed Phase 1 clinical trial of Ketamir-2, a proprietary selective oral NMDA receptor modulator. The randomized, double-blind, placebo-controlled study enrolled 57 healthy volunteers across single and multiple ascending dose cohorts. All participants completed the study with no withdrawals, and no serious adverse events or dose-limiting toxicities were reported. Adverse events were predominantly mild and more frequent in the placebo group. Pharmacokinetic analysis showed rapid oral absorption, dose-proportional Cmax, and no major differences in parameters between Day 1 and Day 5. The half-life of Ketamir-2 ranged from 2.5 to 7 hours, while its active metabolite nor-Ketamir-2 had a half-life of 7 to 9 hours, supporting potential once-daily administration. The U.S. Drug Enforcement Administration determined that Ketamir-2 is not a controlled substance, eliminating a key regulatory hurdle. In validated preclinical models of neuropathic pain, Ketamir-2 demonstrated superior efficacy compared with ketamine, pregabalin, and gabapentin. The company is advancing preparations to submit its Phase 2a clinical protocol for chemotherapy-induced peripheral neuropathy (CIPN) to the FDA under its active IND. These results de-risk the clinical program and position Ketamir-2 as a potential non-opioid, non-controlled treatment for neuropathic pain, addressing a significant unmet need.